2023 World Conference on Lung Cancer (Posters)-EP13.01. Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer with an Emphasis on Oligo-Progressive Disease

EP13.01. Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer with an Emphasis on Oligo-Progressive Disease - PDF(Abstract)

Back to course

Pdf Summary

This study focused on the use of consolidative thoracic radiotherapy for extensive-stage small cell lung cancer (SCLC), specifically in patients with oligo-progressive disease. The researchers reviewed the medical records of 36 SCLC patients treated between June 2017 and December 2021. Of these, 26 patients with limited-stage SCLC were treated with definitive chemoradiotherapy, while the remaining 10 patients with extensive-stage SCLC, who showed partial response or oligo-progressive disease on tumor response evaluation after prior systemic therapy, were treated with consolidative radiotherapy. All patients received a total dose of 52.5 Gy in 25 fractions.<br /><br />The results showed that distant metastasis was the most common type of recurrence in both the definitive and consolidative treatment groups. However, there were no cases of in-field locoregional recurrences. The 1-year overall survival (OS) and disease-free survival (DFS) rates were 87.3% and 56.0%, respectively, for patients treated with a definitive aim, and 88.9% and 60.0%, respectively, for patients treated with a consolidative aim. Moreover, among the 10 patients who received concurrent immunotherapy, 8 are alive with a well-controlled disease status, and 5 of them showed oligo-progressive disease at the thoracic site but are still alive without intrathoracic recurrence.<br /><br />The study concludes that consolidative thoracic radiotherapy is well tolerated and leads to fewer chest recurrences, contributing to long-term survival in well-selected patients with extensive-stage SCLC. It is particularly recommended for patients with oligo-progressive disease and low-bulk thoracic lesions after current chemo-immunotherapy. This information is important for clinicians considering treatment options for patients with extensive-stage SCLC, as it demonstrates the potential benefits of consolidative radiotherapy in improving outcomes for these patients.

Asset Subtitle

Hakyoung Kim

Meta Tag

Speaker Hakyoung Kim

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

consolidative thoracic radiotherapy

extensive-stage small cell lung cancer

SCLC

oligo-progressive disease

medical records

definitive chemoradiotherapy

distant metastasis

overall survival

disease-free survival

concurrent immunotherapy